|
1
|
Sandberg AA and Bridge JA: Updates on the
cytogenetics and molecular genetics of bone and soft tissue tumors:
osteosarcoma and related tumors. Cancer Genet Cytogenet. 145:1–30.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Helman LJ and Meltzer P: Mechanisms of
sarcoma development. Nat Rev Cancer. 3:685–694. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Haydon RC, Luu HH and He TC: Osteosarcoma
and osteoblastic differentiation: a new perspective on oncogenesis.
Clin Orthop Relat Res. 454:237–246. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tang N, Song WX, Luo J, Haydon RC and He
TC: Osteosarcoma development and stem cell differentiation. Clin
Orthop Relat Res. 466:2114–2130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Federman N, Bernthal N, Eilber FC and Tap
WD: The multidisciplinary management of osteosarcoma. Curr Treat
Options Oncol. 10:82–93. 2009. View Article : Google Scholar
|
|
6
|
Rosen G, Marcove RC, Caparros B, Nirenberg
A, Kosloff C and Huvos AG: Primary osteogenic sarcoma: the
rationale for preoperative chemotherapy and delayed surgery.
Cancer. 43:2163–2177. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rosen G, Caparros B, Huvos AG, Kosloff C,
Nirenberg A, Cacavio A, et al: Preoperative chemotherapy for
osteogenic sarcoma: selection of postoperative adjuvant
chemotherapy based on the response of the primary tumor to
preoperative chemotherapy. Cancer. 49:1221–1230. 1982. View Article : Google Scholar
|
|
8
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fu YS, Lin YY, Chou SC, Tsai TH, Kao LS,
Hsu SY, Cheng FC, Shih YH, Cheng H, Fu YY and Wang JY:
Tetramethylpyrazine inhibits activities of glioma cells and
glutamate neuroexcitotoxicity: potential therapeutic application
for treatment of gliomas. Neuro Oncol. 10:139–152. 2008. View Article : Google Scholar
|
|
10
|
Yu K, Chen Z, Pan X, Yang Y, Tian S, Zhang
J, Ge J, Ambati B and Zhuang J: Tetramethylpyrazine-mediated
suppression of C6 gliomas involves inhibition of chemokine receptor
CXCR4 expression. Oncol Rep. 28:955–960. 2012.PubMed/NCBI
|
|
11
|
Zheng CY, Xiao W, Zhu MX, Pan XJ, Yang ZH
and Zhou SY: Inhibition of cyclooxygenase-2 by tetramethylpyrazine
and its effects on A549 cell invasion and metastasis. Int J Oncol.
40:2029–2037. 2012.PubMed/NCBI
|
|
12
|
Zhang Y, Liu X, Zuo T, Liu Y and Zhang JH:
Tetramethylpyrazine reverses multidrug resistance in breast cancer
cells through regulating the expression and function of
P-glycoprotein. Med Oncol. 29:534–538. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yin J, Yu C, Yang Z, He JL, Chen WJ, Liu
HZ, Li WM, Liu HT and Wang YX: Tetramethylpyrazine inhibits
migration of SKOV3 human ovarian carcinoma cells and decreases the
expression of interleukin-8 via the ERK1/2, p38 and AP-1 signaling
pathways. Oncol Rep. 26:671–679. 2011.PubMed/NCBI
|
|
14
|
Wang XB, Wang SS, Zhang QF, Liu M, Li HL,
Liu Y, Wang JN, Zheng F, Guo LY and Xiang JZ: Inhibition of
tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug
resistant human hepatocellular carcinoma cells. Oncol Rep.
23:211–215. 2010.PubMed/NCBI
|
|
15
|
Chen L, Lu Y, Wu JM, Xu B, Zhang LJ, Gao
M, Zheng SZ, Wang AY, Zhang CB, Zhang WW and Lei N: Ligustrazine
inhibits B16F10 melanoma metastasis and suppresses angiogenesis
induced by Vascular Endothelial Growth Factor. Biochem Biophys Res
Commun. 386:374–379. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu Y, Xu Y, Gu X, Hu Y and Wang C:
Molecular mechanism of tetramethylpyrazine to induce human
promyelocytic HL-60 leukemia cells differentiation. Zhongguo Zhong
Yao Za Zhi. 36:3007–3011. 2011.(In Chinese).
|
|
17
|
Fan L, Wang K, Shi Z, Die J, Wang C and
Dang X: Tetramethylpyrazine protects spinal cord and reduces
inflammation in a rat model of spinal cord ischemia-reperfusion
injury. J Vasc Surg. 54:192–200. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lei X, Lv X, Liu M, Yang Z, Ji M, Guo X
and Dong W: Thymoquinone inhibits growth and augments
5-fluorouracil-induced apoptosis in gastric cancer cells both in
vitro and in vivo. Biochem Biophys Res Commun. 417:864–868. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Institute for Laboratory Animal Research.
Guide for the Care and Use of Laboratory Animals. Eighth Edition.
The National Acadamies Press; Washington, D.C., USA: 2011
|
|
20
|
Luong QT, O’Kelly J, Braunstein GD,
Hershman JM and Koeffler HP: Antitumor activity of suberoylanilide
hydroxamic acid against thyroid cancer cell lines in vitro and in
vivo. Clin Cancer Res. 12:5570–5577. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dorfman HD and Weiss SW: Borderline
osteoblastic tumors: problems in the differential diagnosis of
aggressive osteoblastoma and low-grade osteosarcoma. Semin Diagn
Pathol. 1:215–234. 1984.PubMed/NCBI
|
|
22
|
He BC, Chen L, Zuo GW, et al: Synergistic
antitumor effect of the activated PPARgamma and retinoid receptors
on human osteosarcoma. Clin Cancer Res. 16:2235–2245. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li WM, Liu HT, Li XY, Wu JY, Xu G, et al:
The effect of tetramethylpyrazine on hydrogen peroxide-induced
oxidative damage in human umbilical vein endothelial cells. Basic
Clin Pharmacol Toxicol. 106:45–52. 2010.PubMed/NCBI
|
|
24
|
Xiong L, Fang ZY, Tao XN, Bai M and Feng
G: Effect and mechanism of ligustrazine on Th1/Th2 cytokines in a
rat asthma model. Am J Chin Med. 35:1011–1020. 2007. View Article : Google Scholar : PubMed/NCBI
|
